Sartorius (SARTF) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Sartorius is expected to announce quarterly results on April 23, with analysts forecasting $1.37 EPS and $932.28 million in revenue.
• Shares opened at $226.33 (12‑month range $165.00–$226.33) with a market cap of about $7.75 billion and a high P/E of 105.27; the company shows modest liquidity (quick ratio 0.49, current ratio 0.95) and a debt‑to‑equity of 0.89.
• Sartorius is a Germany‑based provider of laboratory and bioprocessing equipment organized into two core divisions: Bioprocess Solutions and Lab Products & Services, serving pharmaceutical, biotech and research customers.

Sartorius (OTCMKTS:SARTF - Get Free Report) will likely be announcing its resultson Thursday, April 23rd. Analysts expect the company to announce earnings of $1.37 per share and revenue of $932.2810 million for the quarter.

Sartorius Stock Performance

Shares of Sartorius stock opened at $226.33 on Thursday. Sartorius has a 12-month low of $165.00 and a 12-month high of $226.33. The stock has a market capitalization of $7.75 billion, a P/E ratio of 105.27 and a beta of 0.98. The company has a 50-day simple moving average of $226.33 and a 200 day simple moving average of $218.92. The company has a quick ratio of 0.49, a current ratio of 0.95 and a debt-to-equity ratio of 0.89.

Sartorius Company Profile

Sartorius AG, trading in the U.S. over the counter under the symbol SARTF, is a Germany-based provider of laboratory and bioprocessing equipment for the pharmaceutical, biotechnology and research industries. The company is organized into two core divisions: Bioprocess Solutions, which focuses on single-use consumables, filtration technologies and upstream and downstream processing systems; and Lab Products & Services, which supplies laboratory instruments, consumables and services, including balances, pipettes, cell counting systems and water purification units.

The Bioprocess Solutions segment serves customers engaged in the development and manufacture of biopharmaceuticals, vaccines and advanced therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.